Brought to you by

PowderJect acquires Celltech Medeva's vaccine business
04 Oct 2000
Executive Summary
PowderJect Pharmaceuticals (needle-free injection systems) will acquire the vaccines business of Celltech Group's Medeva subsidiary for about $79mm (UK55mm) plus a potential earn-out payment of about UK2mm, dependent on sales levels of Medeva's Fluvirin influenza vaccine for the year 2000 season.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Intra-Biotech Deal
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com